Grabar Law Investigates Long-Term Shareholder Claims for Major Corporations
Philadelphia, Monday, 20 October 2025.
Grabar Law Office has launched an investigation into potential claims for long-term shareholders of several firms following a class action lawsuit against Amylyx Pharmaceuticals. This could impact investor confidence.
Amylyx Pharmaceuticals Faces Legal Scrutiny
The legal challenges for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) are intensifying as Grabar Law Office has initiated an investigation into potential claims for long-term shareholders. This follows a significant development where a class action lawsuit alleging securities fraud against the company survived a motion to dismiss on September 30, 2025. The lawsuit accuses Amylyx of misleading investors about the commercial prospects of its drug, Relyvrio, which was withdrawn from the market on April 4, 2024, due to reported issues such as a decline in new patient uptake and high discontinuation rates after six months of treatment [1][2].
Implications for Baxter International and Five Below
In addition to Amylyx, Grabar Law is also investigating Baxter International Inc. (NYSE: BAX) and Five Below, Inc. (NASDAQ: FIVE). Five Below is embroiled in its own securities fraud allegations, with claims that it misrepresented its financial health by failing to execute its retail strategy effectively, leading to a notable stock price decline following disappointing sales results announced on June 5, 2024. The court has allowed these allegations to proceed as of August 25, 2025, indicating ongoing legal challenges for the company [1][2].
Humana Under Investigation
Humana Inc. (NYSE: HUM) is also under scrutiny, with Grabar Law Office investigating potential breaches of fiduciary duties by the company’s officers and directors. The investigation centers on whether Humana misrepresented the pressures on its adjusted earnings per share due to increased medical costs arising from pent-up demand for healthcare services. This probe is part of a broader effort by legal entities to hold companies accountable for their financial disclosures [1][2].
Market and Shareholder Impact
The implications of these investigations are significant for shareholders and the market at large. For instance, Amylyx Pharmaceuticals has seen substantial volatility, with its market capitalization currently standing at $1.59 billion USD as of October 2025. The outcome of these legal proceedings could influence investor confidence and affect the strategic directions of these companies. Stakeholders are advised to remain vigilant as the investigations progress [3][4].